Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression
Open accessThe DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Abstract
Large granular lymphocyte (LGL) leukemia is characterized by the expansion of antigen-activated cytotoxic T lymphocytes. These leukemic cells are resistant to Fas-mediated apoptosis despite expressing high levels of Fas. We found that leukemic LGL from 19 patients displayed high levels of activated STAT3. Treatment of leukemic LGL with the JAK-selective tyrosine kinase inhibitor AG-490 induced apoptosis with a corresponding decrease in STAT-DNA binding activity. Moreover, using an antisense oligonucleotide approach to diminish STAT3 expression, we found that Fas sensitivity was restored in leukemic LGL. AG-490-induced apoptosis in leukemic LGL was independent of Bcl-xL or Bcl-2 expression. However, we found that the Bcl-2-family protein Mcl-1 was significantly reduced by AG-490 treatment. Activated STAT3 was shown to bind an SIE-related element in the murine mcl-1 promoter. Using a luciferase reporter assay, we demonstrated that v-src overexpression in NIH3T3 induced STAT3-dependent transcriptional activity from the mcl-1 promoter and increased endogenous Mcl-1 protein levels. We conclude that STAT3 activation contributed to accumulation of the leukemic LGL clones. These findings suggest that investigation should focus on novel strategies targeting STAT3 in the treatment of LGL leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Other inhibition strategies include the introduction of antisense oligonucleotides, as in the case of the Isis Pharmaceuticals, Inc/AstraZeneca drug in clinical development, designed to cause degradation of STAT3 mRNA or prevent its translation via complementary base pairing, thereby reducing total STAT3 protein levels.105”
From Critical analysis of the potential for targeting STAT3 in human malignancy (2013) · cites this paper as [105]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“the STAT3 protein in the peripheral blood mononuclear cell extracts isolated from patients with large granular lymphocyte leukemia has been reported to bind to the murine SIE motif (9).”
The cited source says what the claim attributes to it.
In the citing paper
“IL-6 plays a significant role in inducing tumor growth as it interacts with the receptor, JAK, to induce STAT-3 activation. STAT-3 then activates oncogenes such as MCL-1 (29) and upregulates genes involved in proliferation such as Cyclin-D1 (30). These activities result in the induction of cancer cell proliferation.”
From Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis (2021) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis
Nicholson, D. W., Ali, A., Thornberry, N. A., Vaillancourt, J. P., Ding, C. K., Gallant, M., Gareau, Y., Griffin, P. R., Labelle, M., Lazebnik, Y. A., et al. (1995) · Nature · doi:10.1038/376037a0 · Cited by 3,979 · cited 2×
“Proteolytic cleavage and activation of a cascade of caspases (death proteases) mediate the cleavage of cellular targets, resulting in programmed cell death (38, 39).”
BackgroundLymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis
Watanabe-Fukunaga, R., Brannan, C. I., Copeland, N. G., Jenkins, N. A., & Nagata, S. (1992) · Nature · doi:10.1038/356314a0 · Cited by 2,885 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundBromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., & Darnell, J. E. (1999) · Cell · doi:10.1016/s0092-8674(00)81959-5 · Cited by 2,790
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130
Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernández-Luna, J. L., Nuñez, G., et al. (1999) · Immunity · doi:10.1016/s1074-7613(00)80011-4 · Cited by 1,638
Self-citationGeneralized lymphoproliferative disease in mice, caused by a point mutation in the fas ligand
Takahashi, T., Tanaka, M., Brannan, C. I., Jenkins, N. A., Copeland, N. G., Suda, T., & Nagata, S. (1994) · Cell · doi:10.1016/0092-8674(94)90375-1 · Cited by 1,528 · cited 1×
“Animal models of lymphoproliferative disorders with autoimmune features such as lpr/lpr and gld/gld mice are characterized by insensitivity to Fasdependent cell death due to mutations in the FasR or FasL, respectively (6, 7).”
BackgroundMCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2.
Kozopas, K. M., Yang, T., Buchan, H. L., Zhou, P., & Craig, R. W. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3516 · Cited by 961
Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein
Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931 · cited 11×
“Transfection of the indicated plasmids into NIH3T3 cells was performed using CaP04, as described previously (28). pM-v-src and pSG5-STAT3β are plasmid vectors expressing v-src and a dominant negative mutant of STAT3, respectively.”
MethodInfluentialSelf-citationInhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor
Meydan, N., Grunberger, T., Dadi, H., Shahar, M., Arpaia, E., Lapidot, Z., Leeder, J. S., Freedman, M., Cohen, A., Gazit, A., et al. (1996) · Nature · doi:10.1038/379645a0 · Cited by 897 · cited 2×
“Therefore, we used a tyrphostin inhibitor (AG-490) selective for the JAKfamily tyrosine kinases to determine whether inhibition of the pathway upstream of STAT activation would affect apoptosis in LGL leukemia cells (32).”
MethodWakao, H., Gouilleux, F., & Groner, B. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06495.x · Cited by 826 · cited 2×
“The degree of binding was determined by electrophoretic analysis on a 5% native polyacrylamide gel as described previously (19, 31).”
BackgroundMethod
Cited by
Items 601–643 of 643
Data from Activation of Stat3 in Human Melanoma Promotes Brain Metastasis
Xie, T.-X., Huang, F.-J., Aldape, K. D., Kang, S.-H., Liu, M., Gershenwald, J. E., Xie, K., Sawaya, R. A., & Huang, S. (2023) · doi:10.1158/0008-5472.c.6494936
Data from Activation of Stat3 in Human Melanoma Promotes Brain Metastasis
Xie, T.-X., Huang, F.-J., Aldape, K. D., Kang, S.-H., Liu, M., Gershenwald, J. E., Xie, K., Sawaya, R. A., & Huang, S. (2023) · doi:10.1158/0008-5472.c.6494936.v1
Kim, B. H., Yin, C., Guo, Q., Bach, E. A., Lee, H., Sandoval, C., Jayabose, S., Ulaczyk‐Lesanko, A., Hall, D. G., & Baeg, G. (2023) · doi:10.1158/1535-7163.c.6531431.v1
Kunnumakkara, A. B., Nair, S. A., Sung, B., Pandey, M. K., & Aggarwal, B. B. (2023) · doi:10.1158/1541-7786.c.6542196
T-Cell Primary Splenic Lymphomas
Gorodetskiy, V. R., & Probatova, N. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15717-2.00020-2
Epigenetic Drugs as Modulators of Tumor Immunogenicity and Host Immune Response
Marchi, E., Pal, I., Manavalan, J. S., Jayappa, K. D., & O’Connor, O. A. (2024) · Wiley eBooks · doi:10.1002/9781119824572.ch28
Lymphoproliferative tumors in rheumatic diseases
Gorodetskiy, V. R., Poddubnaya, I. V., & Nasonov, E. L. (2024) · Rheumatology Science and Practice · doi:10.47360/1995-4484-2024-575-581
Purkiss, D., Lee, I. E., Xu, D., & Wang, J. (2025) · Journal of Clinical and Translational Pathology · doi:10.14218/jctp.2024.00043
Self-citationRoy, A. M., Bawek, S. J., Parikh, R., Faisal, M. S., & Ghione, P. (2025) · eJHaem · doi:10.1002/jha2.70036
“The pathogenesis of LGL remains unclear but it is widely acknowledged that the stimulation of several pathways, including JAK/STAT, FAS/FAS-L, RAS-RAF-1, MEK1-ERK, PI3K/AKT, NK-KB, and the sphingolipid rheostat, is implicated in the proliferation of LGLs [2, 3].”
Cantharidin Suppresses Cell Viability and Induces Apoptosis of SK-N-SH and SH-SY5Y Cells
PEI, J.-S., Lee, H., CHEN, C.-C., Hsu, P., Chen, J., Hsia, T., CHANG, W.-S., BAU, D.-T., & Tsai, C.-W. (2025) · In Vivo · doi:10.21873/invivo.14064
“Constitutive STAT3 activation supports tumor growth and survival by upregulating anti ‑ apoptotic proteins in various human cancer types (53, 54).”
Choi, D.-I., Kim, H. J., Park, D.-G., Lee, J.-H., Porntaveetus, T., & Cho, S. (2025) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2025.106467
Apoptosis regulation in multiple myeloma.
Dimberg, L. Y. (2006) · Uppsala University Publications (Uppsala University)
Yao, R., Chen, Y., Hao, H., Guo, Z., Cheng, X., Ma, Y., Ji, Q., Yang, X., Wang, Y., Li, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13310488
Jakobsen, I., Sundkvist, M., Björn, N., Gréen, H., & Lotfi, K. (2022) · Figshare · doi:10.6084/m9.figshare.21559173
Yao, R., Chen, Y., Hao, H., Guo, Z., Cheng, X., Ma, Y., Ji, Q., Yang, X., Wang, Y., Li, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13310503
Yao, R., Chen, Y., Hao, H., Guo, Z., Cheng, X., Ma, Y., Ji, Q., Yang, X., Wang, Y., Li, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13310497
Yao, R., Chen, Y., Hao, H., Guo, Z., Cheng, X., Ma, Y., Ji, Q., Yang, X., Wang, Y., Li, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13310512
Yao, R., Chen, Y., Hao, H., Guo, Z., Cheng, X., Ma, Y., Ji, Q., Yang, X., Wang, Y., Li, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13310482
Yao, R., Chen, Y., Hao, H., Guo, Z., Cheng, X., Ma, Y., Ji, Q., Yang, X., Wang, Y., Li, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13310506
Jakobsen, I., Sundkvist, M., Björn, N., Gréen, H., & Lotfi, K. (2022) · Figshare · doi:10.6084/m9.figshare.21559176
Yao, R., Chen, Y., Hao, H., Guo, Z., Cheng, X., Ma, Y., Ji, Q., Yang, X., Wang, Y., Li, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13310509
Yao, R., Chen, Y., Hao, H., Guo, Z., Cheng, X., Ma, Y., Ji, Q., Yang, X., Wang, Y., Li, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13310467
Yao, R., Chen, Y., Hao, H., Guo, Z., Cheng, X., Ma, Y., Ji, Q., Yang, X., Wang, Y., Li, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13310470
Jakobsen, I., Sundkvist, M., Björn, N., Gréen, H., & Lotfi, K. (2022) · Figshare · doi:10.6084/m9.figshare.21559179
Karavyraki, M. (2020) · Arrow@dit (Dublin Institute of Technology)
Advances in the treatment of large granular lymphocytic leukemia
Guégan, M., & Lamy, T. (2026) · Expert Review of Hematology · doi:10.1080/17474086.2026.2613733
“Dysregulation of apoptosis is a hallmark of LGLL and is driven by constitutive activation of the JAK/STAT pathway [14–16].”
Ji, Q., Jiang, X., Li, X., Cao, C., Zhang, X., Zhou, M., Ma, S., & Chen, C. (2026) · Annals of Hematology · doi:10.1007/s00277-026-06841-4
“These pathways are key upstream regulators of MCL-1 expression [16 , 17].”
Large granular lymphocyte leukemias — current opinions on diagnosis and management
Wołowiec, D., Korycka, A., & Szostek, M. (2025) · Hematology in Clinical Practice · doi:10.5603/hicp.108770
Xiong, Y. (2016) · theses.fr (ABES) · doi:10.70675/47877607zde95z4ec4z83edz6faa02b0bb59 · Cited by 1
Anti-PAD4 antibodies link autoimmunity to PAD4 with CTL-associated rheumatoid arthritis
Ananth, K., Moosic, K. B., Gómez-Bañuelos, E., Wang, H., Trejo‐Zambrano, M. I., Johnson, R., Kirschmann, J. M., Deddens, T. M., Elghawy, O., Shemo, B. C., et al. (2026) · Annals of the Rheumatic Diseases · doi:10.1016/j.ard.2026.04.006
Self-citationVitamin D Deficiency in Leukemia: Implications for Pathophysiology, Treatment, and Supportive Care
Eskandari, Z., Ryszkiel, I., Ojaroodi, A. F., Bazavar, H., Keramat, S., & Stanek, A. (2026) · Nutrients · doi:10.3390/nu18142227
“Inhibiting the JAK–STAT signaling pathway can induce apoptosis in several cancer cell types, including large granular lymphocytic leukemia (LGLL) cells [53].”
The novel agent VP79s synergistically enhances venetoclax activity in multiple myeloma cells
Pei, Y., Wang, J., Smith, T., Sutton, M., David, J., Gao, T., Hayden, P. J., Browne, P., Previtali, V., Minneci, M., et al. (2026) · Investigational New Drugs · doi:10.1007/s10637-026-01629-9
Self-citationZheng, T., Li, H., Yao, L., Zhang, Y., Feng, L., & Yang, D. (2026) · Cells · doi:10.3390/cells15171624
JAK Kinases in Leukemias, Lymphomas, and Multiple Myeloma
Burger, R., & Gramatzki, M. (2006) · Humana Press eBooks · doi:10.1385/1-59259-962-1:115
“AG490 induced apoptosis in primary LGL leukemia cells and PEL cell lines, which was accompanied by an abrogation of STAT activation and corresponding downregulation of Mcl-1 and survivin, respectively ( 106 ,107).”
BackgroundCantore, S., Musella, G., Bizzoca, M. E., Silva, F. F. V. E., Domenico, M. D., Muzio, A. L., Polimeno, L. M. P., Dioguardi, M., Muzio, L. L., & Ballini, A. (2026) · Frontiers in Oral Health · doi:10.3389/froh.2026.1988813
PTPRT/D MUTATION OR PROMOTER METHYLATION: IMPLICATIONS FOR STAT3 INHIBITION
Peyser, N. D. (2015) · D-Scholarship@Pitt (University of Pittsburgh)
Molecular Genetics of Mature T/NK Neoplasms
Greer, J. P., Davé, U. P., Reddy, N. M., Lovly, C. M., & Mosse, C. A. (2010) · Molecular pathology library · doi:10.1007/978-1-4419-5698-9_25
Metadata
- Authors
- Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.-M., Yang-Yen, H.-F., Karras, J., Jove, R., & Loughran, T. P.
- Affiliations
- University of South Florida (US)
- National Taiwan University (TW)
- Ionis Pharmaceuticals (United States) (US)
- Venue
- Journal of Clinical Investigation
- Published
- 2001-02-01
- Volume
- 107
- Issue
- 3
- Pages
- 351-362
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC199188
- OpenAlex
- W2041204531
- Cited by
- 633
- References
- 60
- Citations by year
- 2026: 7 · 2025: 12 · 2024: 14 · 2023: 20 · 2022: 25 · 2021: 26 · 2020: 31 · 2019: 22 · 2018: 14 · 2017: 27 · 2016: 15 · 2015: 27 · 2014: 46 · 2013: 31 · 2012: 35
- FWCI
- 12.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- Moffitt Cancer Center
- National Institutes of Health (5r21ca078724-02)
- National Cancer Institute (R01CA055652, CA-55652, CA78724)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- large granular lymphocyte leukemia, STAT3 signaling, apoptosis, Mcl-1, Fas resistance, AG490, antisense oligonucleotides, Bcl-2 family proteins, v-Src
- MeSH terms
- Cell Line, DNA-Binding Proteins, Enzyme Inhibitors, Gene Expression Regulation, Humans, Leukemia, Neoplasm Proteins, Phosphorylation, Tumor Cells, Cultured, Blotting, Western, Signal Transduction, Trans-Activators, Oncogene Protein pp60(v-src), Apoptosis, CD8-Positive T-Lymphocytes, Proto-Oncogene Proteins c-bcl-2, Dimerization, Tyrphostins, STAT3 Transcription Factor, Myeloid Cell Leukemia Sequence 1 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.